Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Avallano releases AI-driven ProtocolCopilot

ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols

Piramal Pharma’s Ahmedabad facility completes USFDA PAI

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions

Aster Health Academy announces strategic partnerships with premier Hospitals across India

The academy has secured partnerships with 15 esteemed hospitals

Avallano appoints Michael A. Ibara as Chief Strategy Officer

Ibara will drive AI-powered clinical research innovation

Jubilant Ingrevia receives EIR from USFDA for Unit-1 at Bharuch

This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative

Lupin receives EIR from US FDA for its Somerset manufacturing facility

The facility was inspected from May 7 to May 17, 2024